Stay updated on AstraZeneca PLC ADR Press Releases

Sign up to get notified when there's something new on the AstraZeneca PLC ADR Press Releases page.
Latest website image capture
Clouds background image

Latest updates to the AstraZeneca PLC ADR Press Releases page

  1. Check
    4 days ago
    Change Detected
    Summary
    Added a new press release entry for 04 December 2025 'AstraZeneca advances haematology and cell therapy ambition with largest-ever presence at ASH' and removed the 22 October 2025 entry 'Tezspire approved in the EU for chronic rhinosinusitis with nasal polyps'.
    Difference
    0.9%
    Check dated 2025-12-10T00:40:36.000Z thumbnail image
  2. Check
    12 days ago
    Change Detected
    Summary
    Two new press releases were added: Baxdrostat New Drug Application accepted under FDA Priority Review (02 December 2025) and Imfinzi approved in the US as first and only perioperative immunotherapy for patients with early gastric and gastroesophageal cancers (25 November 2025). Two older items were removed: Datroway's reported survival benefit in metastatic triple-negative breast cancer (19 October 2025) and DESTINY-Breast05/Enhertu results reporting (18 October 2025).
    Difference
    5%
    Check dated 2025-12-02T17:27:40.000Z thumbnail image
  3. Check
    19 days ago
    Change Detected
    Summary
    Added two new press releases (Maryland investment; Koselugo US NF1 approval) and removed two older items (DESTINY-Breast11 pCR details; Tezspire US approval for CRS with nasal polyps).
    Difference
    5%
    Check dated 2025-11-25T13:43:33.000Z thumbnail image
  4. Check
    33 days ago
    Change Detected
    Summary
    Added a new Baxdrostat Phase III results press release with dates (9M and Q3 2025) and Bax24 details. Removed two older press releases (Saphnelo CHMP recommendation and POTOMAC trial) from the listing.
    Difference
    4%
    Check dated 2025-11-11T03:29:04.000Z thumbnail image
  5. Check
    40 days ago
    Change Detected
    Summary
    Added four new press release items to the top of the Press Releases page, including Gefurulimab MG-ADL PREVAIL Phase III results and related meeting references with dates in October 2025. Removed several navigation elements, social media links, and older press releases from the page.
    Difference
    7%
    Check dated 2025-11-03T21:41:23.000Z thumbnail image
  6. Check
    55 days ago
    Change Detected
    Summary
    Summary of changes: There are several high-importance additions signaling new approvals and trial results (eg, Enhertu-related outcomes, Tezspire and Saphnelo developments, conditioning on regulatory status) and date stamps; deletions retract or modify prior trial-result claims and corporate actions (eg, Baxdrostat, Enhertu trial outcomes, listing harmonisation, and some approval predictions). Overall, the additions introduce newer positive trial results and regulatory updates, while deletions remove or soften some earlier claims, indicating an overall movement toward updated, more nuanced drug development news rather than a simple expansion of existing content.
    Difference
    91%
    Check dated 2025-10-20T17:12:17.000Z thumbnail image

Stay in the know with updates to AstraZeneca PLC ADR Press Releases

Enter your email address, and we'll notify you when there's something new on the AstraZeneca PLC ADR Press Releases page.